---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Place in treatment, anticipated use, and care setting. Topics: Summary: target population, Summary: position relative to current first-line therapy by HLA status and disease distribution, Summary: anticipated use and care setting, Darovasertib plus crizotinib in the targeted agents section of the guideline, and 14 further topics. 18 evidence topics quoted from 26 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: target population

The FDA has agreed to review the new drug application for darovasertib in combination with crizotinib for patients with first-line HLA-A∗02:01-negative metastatic uveal melanoma under the Real-Time Oncology Review program, and the submission includes data from OptimUM-02 and OptimUM-01. OptimUM-02 enrolled adults 18 years and older with histologically or cytologically confirmed metastatic uveal melanoma that is HLA-A∗02:01 negative, no prior systemic therapy in the metastatic or advanced setting and no prior regional or liver-directed therapy (ablation or resection of oligometastatic disease and neoadjuvant or adjuvant therapy were allowed), measurable disease per RECIST 1.1, ECOG performance status 0 or 1, and a life expectancy of at least 3 months. Participants could be initially diagnosed with metastatic disease or have metastases after therapy for localized uveal melanoma. The trial excluded prior treatment with a PKC inhibitor or an inhibitor directly targeting MET, symptomatic or untreated CNS metastases, a high risk of syncope or falls, stroke within the last 6 months, and clinically significant cardiac disease. OptimUM-01 data, including the phase 2 expansion in 101 HLA-A∗02:01-positive participants, are intended to support discussions on expanding the labeled indication. Crizotinib is FDA approved for ALK- or ROS1-positive metastatic non-small cell lung cancer, ALK-positive anaplastic large cell lymphoma, and ALK-positive inflammatory myofibroblastic tumor. Identifying the population requires HLA-A∗02:01 typing, which a reference laboratory reports in 3 to 7 days; in a deidentified database of 219 patients, HLA-A∗02:01 status was negative in 42.9% and unknown in 15.1%.

Source: [IDEAYA Biosciences press release, Real-Time Oncology Review (2026)](https://media.ideayabio.com/2026-04-30-IDEAYA-Biosciences-to-Initiate-New-Drug-Application-Submission-from-the-Darovasertib-OptimUM-02-Trial-under-the-Oncology-Center-of-Excellence-Real-time-Oncology-Review-RTOR-Program); [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf); [IDEAYA Biosciences Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526445294/idya-20260930.htm); [ClinicalTrials.gov NCT05987332](https://clinicaltrials.gov/study/NCT05987332); [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01); [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update); [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update); [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf); [Labcorp test 167107, HLA A A*02:01-Specific](https://www.labcorp.com/tests/167107/hla-a-a-02-01-specific); [Salama et al. (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-1-5/contemporary-real-world-patient-characteristics-treatment-patterns-and-clinical-outcomes-in-metastatic-uveal-melanoma-in-the-united-states)

<a id="topic-2.2.2.2-2"></a>

### Summary: position relative to current first-line therapy by HLA status and disease distribution

For HLA-A∗02:01-positive patients, tebentafusp is approved by the FDA and the EMA as first-line systemic treatment and is recommended as standard of care in the first-line metastatic setting unless liver-directed treatment is required first for tumour debulking. For HLA-A∗02:01-negative patients, in the absence of a standard of care, liver-directed therapies (PHP and IHP), anti-PD-1-based immunotherapies, and clinical trial enrolment are the preferred options; patients with extensive disease are encouraged to enter a clinical trial, with percutaneous hepatic perfusion or checkpoint inhibitors alone or in combination as alternatives, and local therapies are proposed for limited hepatic metastases. By disease distribution, oligometastatic disease confined to the liver can be considered for resection or thermal ablation, and multifocal metastases confined to the liver for regional perfusion.

Darovasertib plus crizotinib would enter first-line treatment of HLA-A∗02:01-negative disease. In 313 participants of the phase 2b/3 portion of OptimUM-02, the combination reduced the risk of progression by blinded independent central review by 58% (hazard ratio 0.42; 95% CI 0.30 to 0.59) compared with investigator's choice of pembrolizumab, ipilimumab plus nivolumab, or dacarbazine, with median progression-free survival of 6.9 versus 3.1 months. Dr. Lutzky stated that tebentafusp remains the preferred first-line therapy for HLA-A∗02:01-positive disease, that darovasertib plus crizotinib may become an alternative for selected patients with rapidly progressive disease, extensive liver involvement, or a need for prompt tumor shrinkage, and the same report states that darovasertib plus crizotinib “appears likely to become the preferred systemic first-line option”; percutaneous hepatic perfusion remains important for liver-dominant disease with preserved hepatic function. Faculty in an OncLive report did not support combining darovasertib plus crizotinib with tebentafusp upfront because of overlapping toxicity, or frontline dual checkpoint inhibition outside a clinical trial. The ESMO 2026 poster authors describe the combination as a potential “new oral standard of care” in this setting, and IDEAYA cites OptimUM-01 in support of its potential for patients irrespective of HLA-A∗02:01 status and line of therapy. The progression-free survival data may enable an accelerated approval filing, with overall survival from a prespecified interim analysis expected in mid-2027 to support full approval.

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Rodrigues et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40628555/); [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma); [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf); [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/); [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape); [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma); [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm); [IDEAYA Biosciences press release, OptimUM-02 ASCO 2026 data (2026)](https://media.ideayabio.com/2026-06-01-IDEAYA-Biosciences-and-Servier-Provide-Complete-Data-from-Phase-2-3-Registrational-OptimUM-02-Trial-of-the-Darovasertib-Combination-in-First-Line-HLA-A2-01-Negative-Metastatic-Uveal-Melanoma-in-a-Late-Breaking-Oral-Presentation-at-ASCO); [IDEAYA Biosciences press release, second quarter 2026 results (2026)](https://media.ideayabio.com/2026-08-04-IDEAYA-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update)

<a id="topic-2.2.2.2-3"></a>

### Summary: anticipated use and care setting

The combination is taken orally: participants received darovasertib 300 mg twice daily plus crizotinib 200 mg twice daily, the recommended phase 2 dose, whereas the crizotinib label recommends 250 mg twice daily for NSCLC and lists 200 mg twice daily as its first dose reduction; crizotinib capsules are taken with or without food. The sponsor states that “A daily oral targeted regimen has the potential to improve compliance”. Tebentafusp, by comparison, requires weekly intravenous administration with observation at initiation, inpatient monitoring for the first 3 to 4 infusions in an experienced institution before subsequent infusions in a community clinic, and considerable pharmacy resources to prepare each dose.

Expert panelists noted that an oral regimen “removes the referral-forcing function that intravenous therapies create”, while the combination carries nausea, vomiting, diarrhea, and edema that low-volume community centers may not be able to manage; one panelist proposed a mandatory link to an expert center with community physicians managing maintenance. The short half-life of the combination typically makes brief holds and dose reductions, with dietary counseling, sufficient to keep patients on therapy, and the mean delivered dose intensity was 80% or more. Supportive measures for orthostatic hypotension during initial dosing include adequate hydration, initial withholding of blood pressure medications, and avoiding abrupt posture changes. The crizotinib label calls for liver function tests every 2 weeks during the first 2 months and then monthly, and ECG and electrolyte monitoring in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or QT-prolonging medications; OptimUM-02 excluded strong CYP3A4/5 inducers or inhibitors and narrow therapeutic index CYP3A4/5 substrates. A 2026 guideline recommends discussing therapeutic options at an oncology or molecular tumour board in reference centres with expertise in uveal melanoma, and a community oncology practice reports treating metastatic uveal melanoma in most of its clinic locations, a disease a general oncologist may see only once every several years. Darovasertib is currently available only through clinical trials; IDEAYA has initiated planning for potential commercial operations and expects a moderately sized specialty sales force to reach the relevant specialists, and Servier will be responsible for commercialization outside the U.S.

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf); [McKean et al. (2025)](https://www.ideayabio.com/sites/default/files/publications/2026-11/SMR-2025-McKean-OptimUM-01.pdf); [Pfizer XALKORI prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202570s036lbl.pdf); [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf); [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802); [CADTH reimbursement recommendation, tebentafusp (2023)](https://www.canjhealthtechnol.ca/index.php/cjht/article/download/PC0290/1148?inline=1); [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape); [EU CTIS 2023-506686-66-01](https://euclinicaltrials.eu/ctis-public-api/retrieve/2023-506686-66-01); [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/); [Resnick (2026)](https://www.ajmc.com/view/considerations-for-use-of-tebentafusp-a-bite-approved-for-rare-high-risk-uveal-melanoma); [IDEAYA Biosciences clinical trials and expanded access policy](https://www.ideayabio.com/clinical-trials); [IDEAYA Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1676725/000119312526054533/idya-20251231.htm)

<a id="topic-2.2.2.2-4"></a>

### Darovasertib plus crizotinib in the targeted agents section of the guideline

> “An interim analysis of a phase II trial ( NCT03947385 ) evaluating darovasertib in combination with the mesenchymal-epithelial transition factor (c-MET) inhibitor crizotinib showed ORR of 31% in the first 35 assessable patients.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.2-5"></a>

### Tebentafusp as the approved first-line systemic treatment for HLA-A∗02:01-positive disease

> “In 2021, tebentafusp demonstrated OS benefit in the HLA-A∗02:01-positive first-line population; 23 the first time a systemic treatment showed a survival benefit in metastatic UM.”
> “Tebentafusp has been approved by the FDA and the European Medicines Agency (EMA) as first-line systemic treatment in HLA-A∗02:01-positive patients with metastatic UM.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.2-6"></a>

### Sequencing by HLA-A∗02:01 status in the French expert consensus guidelines

> “Systemic therapy with tebentafusp is the standard of care for HLA-A*02:01-positive patients.”
> “For HLA-A*02:01-negative patients with extensive disease, treatment options are limited.”
> “They are encouraged to participate in a clinical trial, alternatively, percutaneous hepatic perfusion, ICI alone or in combination can be proposed.”
> “Local therapies are proposed for patients with limited hepatic metastases, from liver surgery to isolated hepatic perfusion and chemoembolisation for patients with more extensive hepatic involvement.”

Source: [Rodrigues et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40628555/)

<a id="topic-2.2.2.2-7"></a>

### Clinical trials for HLA-A∗02:01-negative patients and combination of tebentafusp with locoregional therapy in a 2026 review

> “The first-line treatment for HLA-A*02:01-positive MUM patients of tebentafusp can be combined with locoregional therapies upfront or in case of oligoprogression on tebentafusp following multidisciplinary tumor board (MTB) discussion.”
> “HLA-A*02:01-negative MUM patients should be offered participation in clinical trials.”
> “Innovative drugs, such as DYP688 or the combination of darovasertib and crizotinib, are promising.”

Source: [Piperno-Neumann et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12962742/)

<a id="topic-2.2.2.2-8"></a>

### Discussant view of first-line sequencing by HLA-A∗02:01 status after the OptimUM-02 presentation

> “For HLA-A*02:01–positive metastatic uveal melanoma, Dr. Lutzky said tebentafusp remains the preferred first-line therapy because of its proven survival benefit.”
> “However, he said darovasertib plus crizotinib may become an attractive alternative for selected patients with rapidly progressive disease, extensive liver involvement, or a need for prompt tumor shrinkage, once available and as additional data emerge.”
> “Darovasertib plus crizotinib appears likely to become the preferred systemic first-line option.”
> “He added that liver-directed therapies remain important, particularly percutaneous hepatic perfusion for appropriate patients with liver-dominant disease and preserved hepatic function.”
> “Clinical trials also remain vital across HLA groups and lines of therapy, he said, because metastatic uveal melanoma is still not curable for most patients.”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-2.2.2.2-9"></a>

### Discussant statement that the question has shifted to sequencing

> “Nonetheless, the efficacy signal is sufficiently strong that I believe the burden of proof has now shifted away from demonstrating activity and toward defining optimal sequencing,”

Source: [Barbor (2026)](https://ascopost.com/articles/2026/08-august/darovasertib-plus-crizotinib-may-set-new-first-line-standard-in-hla-a2-negative-metastatic-uveal-melanoma/)

<a id="topic-2.2.2.2-10"></a>

### Expert workshop positions on darovasertib plus crizotinib, combination with tebentafusp, and first-line dual checkpoint inhibition

> “Results from OptimUM-02 established a meaningful ORR for darovasertib plus crizotinib in HLA-A*02:01–negative metastatic uveal melanoma.”
> “Faculty largely closed the door on combining darovasertib/crizotinib with tebentafusp upfront due to overlapping toxicity concerns.”
> “Faculty aligned on not using dual immune checkpoint inhibitor (ICI) therapy frontline outside a clinical trial and sequencing ICIs thoughtfully relative to liver-directed therapy and cell-based approaches.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.2-11"></a>

### Oral administration, community management, and linkage to expert centers

> “Its oral route raises concerns about community misuse; proactive toxicity education and expert-center linkage are essential.”
> “However, the panelists warned that although an oral regimen removes the referral-forcing function that intravenous therapies create, the combination carries toxicities such as nausea, vomiting, diarrhea, and edema.”
> “These toxicities often require sophisticated management, which low-volume community centers may not be able to provide, Chmielowski said.”
> “To address this, Orloff proposed a mandatory link to an expert center with a prebuilt contingency plan, with community physicians managing maintenance.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

<a id="topic-2.2.2.2-12"></a>

### Daily oral regimen described by the sponsor

> “A daily oral targeted regimen has the potential to improve compliance, treatment outcomes and quality of life for UM patients”

Source: [IDEAYA Biosciences corporate presentation, November 2026 (2026)](https://ir.ideayabio.com/image/20261103_IDEAYA+Corporate+Presentation_November+2026_vF.pdf)

<a id="topic-2.2.2.2-13"></a>

### Weekly intravenous tebentafusp with observation at initiation, as contrasted by the OptimUM-01 investigators

> “Tebentafusp, the only (US) Food and Drug Administration (FDA)–approved systemic therapy, is restricted to a subset of human leukocyte antigen (HLA)-A*02:01–positive patients”
> “Additionally, this therapy requires weekly intravenous administration with observation periods at initiation.”

Source: [McKean et al. (2026b)](https://ascopubs.org/doi/10.1200/JCO-26-00802)

<a id="topic-2.2.2.2-14"></a>

### Inpatient and outpatient initiation of tebentafusp in practice

> “However, several faculty noted they still prefer inpatient monitoring for the initial doses, particularly in older patients with high disease burden.”
> “This is one of the last treatments with a mandatory observation requirement.”

Source: [OncLive (2026)](https://www.onclive.com/view/tebentafusp-darovasertib-and-cell-based-therapies-emerge-as-pillars-of-an-evolving-uveal-melanoma-treatment-landscape)

> “Despite the lack of ICANS and low rate of grade 3 or 4 CRS, our practice has not yet begun to initiate tebentafusp patients in the outpatient setting like we have for all other BiTEs.”
> “However, to reduce barriers to access, we look forward to developing a model that will allow us to initiate newly identified patients on tebentafusp in an all-outpatient setting.”

Source: [Resnick (2026)](https://www.ajmc.com/view/considerations-for-use-of-tebentafusp-a-bite-approved-for-rare-high-risk-uveal-melanoma)

<a id="topic-2.2.2.2-15"></a>

### Treatment in community oncology practice and clinical pathways for a rare disease

> “Whether through its collaboration with regional academic medical centers or by local diagnosis, NECS has treated patients with metastatic uveal melanoma in most of its clinic locations.”
> “Clinical pathways assist in appropriate patient treatment selection, especially for rare disease states that a general oncologist in the community setting may see only once every several years.”

Source: [Resnick (2026)](https://www.ajmc.com/view/considerations-for-use-of-tebentafusp-a-bite-approved-for-rare-high-risk-uveal-melanoma)

<a id="topic-2.2.2.2-16"></a>

### Tumor board discussion in reference centers and access to expert centers

> “Therapeutic options should be discussed at an oncology or molecular tumour board (MTB) in reference centres with expertise in UM.”
> “The MTB should at minimum include ophthalmologists (optionally), pathologists, interventional radiologists, liver surgeons, radiation and medical oncologists.”
> “National networks and patient advocacy groups may help facilitate patient access to expert centres and organise local patient care.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.2.2-17"></a>

### Sponsor and investigator positioning as a first-line standard for HLA-A∗02:01-negative disease

> “OptimUM-02 is the first randomized study to demonstrate a statistically significant and clinically meaningful benefit in PFS in the clinical setting of first-line HLA-A*02:01-negative metastatic uveal melanoma.”

Source: [IDEAYA Biosciences press release, OptimUM-02 topline results (2026)](https://media.ideayabio.com/2026-04-13-IDEAYA-Biosciences-and-Servier-Announce-Positive-Topline-Results-from-Phase-2-3-Registrational-Trial-OptimUM-02-of-Darovasertib-in-Combination-with-Crizotinib-in-First-line-HLA-A-02-01-Negative-Metastatic-Uveal-Melanoma)

> “Collectively, these findings further support the potential of with darova+criz as a new oral standard of care for patients with HLA-A*02:01-negative mUM in the first-line setting”

Source: [Piperno-Neumann et al. (2026c)](https://www.ideayabio.com/sites/default/files/publications/2026-11/ESMO-2026-Piperno-Neumann-OptimUM-02.pdf)

<a id="topic-2.2.2.2-18"></a>

### Sponsor and investigator positioning across HLA-A∗02:01 status and lines of therapy

> “The randomized OptimUM-02 results demonstrate the potential for darovasertib plus crizotinib to establish a new first line standard for patients with HLA-A*02:01-negative disease, while the OptimUM-01 findings reinforce its potential to become a new standard of care for the broader population of patients irrespective of HLA-A*02:01 status and line of therapy.”

Source: [IDEAYA Biosciences press release, ESMO 2026 data (2026)](https://media.ideayabio.com/2026-10-19-IDEAYA-Biosciences-and-Servier-Announce-Data-From-Three-Clinical-Trials-at-ESMO-2026-Supporting-the-Potential-of-Darovasertib-to-Become-a-Foundational-New-Therapy-for-Patients-Across-the-Treatment-Journey-of-Uveal-Melanoma)

> “The OptimUM-01 update focused on the Phase 2 expansion results in 101 HLA-A*02:01-positive patients, including both treatment naïve and 2L patients who received prior tebentafusp.”
> “Collectively, the data support the broad potential of the darovasertib combination to drive meaningful clinical benefits for patients with mUM, irrespective of HLA-A*02:01 allele status or line of therapy.”

Source: [IDEAYA Biosciences press release, third quarter 2026 results (2026)](https://media.ideayabio.com/2026-11-03-IDEAYA-Biosciences-Reports-Financial-Results-for-the-Third-Quarter-2026-and-Provides-a-Business-Update)

Additional sources: [National Comprehensive Cancer Network Uveal Melanoma guideline](https://www.nccn.org/professionals/physician_gls/pdf/uveal.pdf)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
